124 results
Page 5 of 7
424B5
z3jx481s538v2ce8
25 Sep 19
Prospectus supplement for primary offering
4:58pm
8-K
EX-99.1
qk8jsj
6 Aug 19
BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
8:06am
8-K
EX-99.1
xzrfnwwh yxvru0qw7
22 Jul 19
Regulation FD Disclosure
9:29am
8-K
EX-99.2
6sc5il3 nwow
22 Jul 19
Regulation FD Disclosure
9:29am
8-K
EX-1.1
u1cki2afs17
20 May 19
Entry into a Material Definitive Agreement
9:28am
424B5
turr27wun
20 May 19
Prospectus supplement for primary offering
9:18am
8-K
EX-99.2
hsb6pb etwlb
20 May 19
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
9:04am
8-K
EX-99.1
2j0gon9qeaa
20 May 19
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
9:04am
8-K
mdrj4pqput93twdlkgk
20 May 19
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
9:04am
8-K
EX-99.1
uebibh 7pzn
7 May 19
BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update
8:17am
DEF 14A
ik4ukf75 0dcv
1 Apr 19
Definitive proxy
5:20pm
8-K
EX-99.1
6m04un
1 Apr 19
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
4:08pm
8-K
EX-99.1
h96tijkft5e 3ynyfnr
25 Mar 19
Other Events
4:45pm
S-3
kpb7vm
14 Mar 19
Shelf registration
4:45pm
8-K
EX-99.1
y7hhnxpxbpdh69fzolcu
12 Mar 19
Other Events
5:21pm
10-K
d2c5r1x z8x
12 Mar 19
Annual report
12:00am
8-K
EX-99.1
5mp51
11 Mar 19
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
4:38pm